Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

BACKGROUND Carbapenem antibiotics are used to treat serious infections caused by extended-spectrum beta-lactamase-carrying pathogens. Carbapenem resistance has been unusual in isolates of Klebsiella pneumoniae. In this study, the prevalence and molecular epidemiologic characteristics of carbapenem-resistant K pneumoniae are analyzed, and the experience involving 2 hospital outbreaks is described. METHODS A citywide surveillance study was conducted in hospitals in Brooklyn. An observational study involving subsequent outbreaks at 2 hospitals was undertaken. Isolates were genetically fingerprinted by ribotyping and were examined for the presence of KPC-type carbapenem-hydrolyzing beta-lactamases. RESULTS Of 602 isolates of K pneumoniae collected during the citywide surveillance study, 45% had extended-spectrum beta-lactamases. Of the extended-spectrum beta-lactamase-producing isolates, 3.3% carried the carbapenem-hydrolyzing beta-lactamase KPC-2. Several isolates were reported by the clinical microbiology laboratories as being susceptible to imipenem. Although all the isolates were resistant using agar diffusion methods, minimal inhibitory concentrations of imipenem were substantially lower for several isolates using standard broth microdilution tests and were highly dependent on the inoculum used. Two hospitals experienced the rapid spread of carbapenem-resistant isolates involving 58 patients. Overall 14-day mortality for bacteremic patients was 47%. Most isolates belonged to a single ribotype. CONCLUSIONS Carbapenem-resistant K pneumoniae isolates are rapidly emerging in New York City. The spread of a strain that possesses a carbapenem-hydrolyzing beta-lactamase has occurred in regional hospitals. Because these isolates are resistant to virtually all commonly used antibiotics, control of their spread is crucial. However, automated systems used for susceptibility testing may not accurately identify all these isolates, which will severely hamper control efforts.

[1]  P. Bradford,et al.  Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  G. Jacoby,et al.  The new beta-lactamases. , 2005, The New England journal of medicine.

[3]  P. Courvalin,et al.  Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration. , 2000, The Journal of antimicrobial chemotherapy.

[4]  D. Landman,et al.  Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. , 2002, Archives of internal medicine.

[5]  A. Harris,et al.  Identification of beta-lactamases by analytical isoelectric focusing: correlation with bacterial taxonomy. , 1976, Journal of general microbiology.

[6]  R. Cantón,et al.  Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  K. Bush,et al.  Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein , 1997, Antimicrobial agents and chemotherapy.

[8]  R. Gaynes,et al.  Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. , 1999, Critical care medicine.

[9]  W. Trick,et al.  Control of vancomycin-resistant enterococcus in health care facilities in a region. , 2001, The New England journal of medicine.

[10]  J. Bartlett.  International prospective study of klebsiella pneumoniae bacteremia: Implications of extended-spectrum β-lactamase production in nosocomial infections , 2004 .

[11]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[12]  K. Bush,et al.  Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae , 2001, Antimicrobial Agents and Chemotherapy.

[13]  E. S. Moland,et al.  Occurrence of Newer β-Lactamases in Klebsiella pneumoniae Isolates from 24 U.S. Hospitals , 2002, Antimicrobial Agents and Chemotherapy.

[14]  V. Miriagou,et al.  Imipenem Resistance in a Salmonella Clinical Strain Due to Plasmid-Mediated Class A Carbapenemase KPC-2 , 2003, Antimicrobial Agents and Chemotherapy.

[15]  D. Landman,et al.  Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  P. Bradford,et al.  Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[18]  CDC definitions for nosocomial infections, 1988. , 1989, The American review of respiratory disease.

[19]  D. Landman,et al.  Detection of KPC Carbapenem-Hydrolyzing Enzymes in Enterobacter spp. from Brooklyn, New York , 2005, Antimicrobial Agents and Chemotherapy.

[20]  Neil Woodford,et al.  Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center , 2004, Antimicrobial Agents and Chemotherapy.

[21]  L. Rice,et al.  Extended-Spectrum β-Lactamases in Klebsiella pneumoniae Bloodstream Isolates from Seven Countries: Dominance and Widespread Prevalence of SHV- and CTX-M-Type β-Lactamases , 2003, Antimicrobial Agents and Chemotherapy.

[22]  G. Jacoby,et al.  Roles of β-Lactamases and Porins in Activities of Carbapenems and Cephalosporins against Klebsiella pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.

[23]  R. Goering,et al.  Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. , 2003, The Journal of antimicrobial chemotherapy.

[24]  R. Moellering,et al.  Antimicrobial-drug resistance. , 1996, The New England journal of medicine.